Cargando…
Systemic exposure following intravitreal administration of therapeutic agents: an integrated pharmacokinetic approach. 2. THR-687
Intravitreal (IVT) injection remains the preferred administration route of pharmacological agents intended for the treatment of back of the eye diseases such as diabetic macular edema (DME) and neovascular age-related macular degeneration (nvAMD). The procedure enables drugs to be delivered locally...
Autores principales: | Vanhove, Marc, Wagner, Jean-Marc, Noppen, Bernard, Jonckx, Bart, Vermassen, Elke, Stitt, Alan W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604881/ https://www.ncbi.nlm.nih.gov/pubmed/34302261 http://dx.doi.org/10.1007/s10928-021-09774-9 |
Ejemplares similares
-
Systemic exposure following intravitreal administration of therapeutic agents: an integrated pharmacokinetic approach. 1. THR-149
por: Vanhove, Marc, et al.
Publicado: (2021) -
A novel assay based on pre-equilibrium titration curves for the determination of enzyme inhibitor binding kinetics
por: Noppen, Bernard, et al.
Publicado: (2021) -
Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular Edema
por: Khanani, Arshad M., et al.
Publicado: (2021) -
Targeting Plasma Kallikrein With a Novel Bicyclic Peptide Inhibitor (THR-149) Reduces Retinal Thickening in a Diabetic Rat Model
por: Van Bergen, Tine, et al.
Publicado: (2021) -
Configuring Windows 8: exam ref 70-687
por: Halsey, Mike, et al.
Publicado: (2013)